Lung adenocarcinoma with concurrent exon 19 EGFR mutation and ALK rearrangement responding to erlotinib

J Thorac Oncol. 2011 Nov;6(11):1962-3. doi: 10.1097/JTO.0b013e31822eec5e.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma / drug therapy
  • Adenocarcinoma / genetics
  • Adenocarcinoma / pathology
  • Aged
  • Anaplastic Lymphoma Kinase
  • ErbB Receptors / genetics*
  • Erlotinib Hydrochloride
  • Exons / genetics*
  • Female
  • Gene Rearrangement*
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / genetics*
  • Lung Neoplasms / pathology
  • Mutation / genetics*
  • Quinazolines / therapeutic use*
  • Receptor Protein-Tyrosine Kinases / genetics*
  • Treatment Outcome

Substances

  • Quinazolines
  • Erlotinib Hydrochloride
  • ALK protein, human
  • Anaplastic Lymphoma Kinase
  • EGFR protein, human
  • ErbB Receptors
  • Receptor Protein-Tyrosine Kinases